ArticleInfection2026
Corallopyronin A exhibits potent activity against staphylococci including MRSA and isolates from prosthetic infections.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Constrained RNA polymerase mutational pathways distinguish corallopyronin A resistance from rifampicin resistance in staphylococci.Scientific reports · 2026Article
- Activity of Corallopyronin A Against ESKAPEE Pathogens: Potential and Translational Implications.Antibiotics (Basel, Switzerland) · 2026Article
- Breaking Down Barriers: CorA Effectively Targets Staphylococcal Biofilms in Vitro and in Vivo.ChemMedChem · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThis study evaluates the in vitro antimicrobial activity of Corallopyronin A (CorA) against a diverse collection of Staphylococcus aureus and coagulase-negative staphylococci (CNS), comprising both laboratory strains and clinical isolates. The dataset includes methicillin-resistant and methicillin-susceptible strains, as well as small colony variants (SCVs), to assess its therapeutic potential in staphylococcal infections.
methodsA total of 116 staphylococcal strains, comprising clinical isolates and laboratory strains, were subjected to minimum inhibitory concentration (MIC) testing. Minimum bactericidal concentrations (MBCs) were determined for a subset of 70 strains. Time-kill assays were conducted for five S. aureus strains using 4 × MIC of CorA. Additionally, checkerboard assays were performed with 11 antibiotics to evaluate potential additive or synergistic interactions.
resultsCorA demonstrated potent antimicrobial activity with MIC values ranging from 0.125 to 2 mg/L. The MIC
conclusionsCorA shows strong in vitro activity against a broad range of staphylococcal strains, particularly methicillin-resistant isolates. Its additive effects with clinically relevant antibiotics further support its potential in combination therapy for the treatment of resistant staphylococcal infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.